Skip to content

The All Ireland Infectious Diseases Cohort Project

The All Ireland Infectious Diseases Cohort Project - AIID Cohort Project

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06410053
Acronym
AIID
Enrollment
10000
Registered
2024-05-10
Start date
2011-03-31
Completion date
2024-12-31
Last updated
2024-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious Disease

Keywords

Human Immunodeficiency virus, COVID-19, Viral hepatitis, Skin and soft tissue infections, Bone infection

Brief summary

The All-Ireland Infectious Diseases (AIID) Cohort is a multicentre, prospective, longitudinal observational cohort that enrols consecutive adult subjects attending participating institutions for infectious disease services. This is an ongoing prospective observational cohort of unlimited duration.

Detailed description

The All-Ireland Infectious Diseases cohort study (AIID Cohort) is enrolling patients at a number of Irish Hospitals with infectious diseases, including Covid-19. The AIID Cohort is a multicentre, prospective, longitudinal, observational cohort that enrols consecutive adult subjects (\>18 years old) attending hospitals services for management of infections. Subjects provide consent for use of routine clinical and laboratory data for research. All data is collected by a combination of retrospective medical note review and extraction of data from electronic health records. At a minimum, the following data items are to be collected at enrolment and subsequent clinic visits: 1. Demography and basic information (e.g. date of birth, gender, country of origin, ethnicity, anthropometric assessments, and reasons for the attendance, date or year for disease diagnosis and transmission risk. 2. Laboratory data: Relevant routine virological (including genotyping) and immunological data for characterisation of the HIV infection, TB, hepatitis C, COVID-19 and other relevant co-infections will also be collected as well as other relevant clinical routine data on tolerability and safety (i.e., renal, liver, lipids) 3. Medical treatment: All medications, including start-and stop dates and reason for discontinuation, adherence. Concomitant medical treatment related to co-infections and co-morbidities. 4. Clinical events: hospitalisation, diseases specific relevant active and previous diagnosis (e.g., AIDS and non-AIDS events, including comorbidities). In addition, subjects are asked to provide biological samples for up to five occasions every six months for bio-banking for host profiling and pathogen bio-repository. To provide flexibility for participants around requirements for fasting or scheduling, participants may be asked to attend to provide samples for biobanking outside of routine scheduled clinic visits. These stored samples provide the opportunity for future research studies investigating host factors associated with the response to infection. The AIID Cohort is approved by local institutional review boards and all participants provide written, informed consent. Data and samples within the AIID Cohort are accessed through standardised Data Access Guidelines and all approved Data Access Requests are approved by the local Ethics Committee.

Interventions

None listed

Sponsors

Beaumont Hospital
CollaboratorOTHER
Children's Health Ireland
CollaboratorOTHER_GOV
Cork University Hospital
CollaboratorOTHER
Mater Misericordiae University Hospital
CollaboratorOTHER
Our Lady of Lourdes Hospital, Drogheda
CollaboratorOTHER_GOV
St. James's Hospital, Ireland
CollaboratorOTHER
St. Luke's Hospital, Ireland
CollaboratorOTHER
St Vincent's University Hospital, Ireland
CollaboratorOTHER
Wexford General Hospital
CollaboratorUNKNOWN
University College Dublin
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* ≥ 18 years of age patients attending clinical services of participating institutions with issues related to infectious diseases. * Willing and able to provide informed consent or * Provide deferred assent if an incapacitated or unconscious patient is unable to provide informed consent

Exclusion criteria

* Patients under 18 years of age * Patients with learning disabilities, mental illness, or dementia

Design outcomes

Primary

MeasureTime frameDescription
Establishment of data rich cohortthrough study completion, an average of 1 yearOverall number of recruited participants and number of recruited participants with major conditions (COVID-19, HIV, TB)

Secondary

MeasureTime frameDescription
Cohort retentionthrough study completion, an average of 1 yearNumber of subjects in care or mortality
Cohort associated metadatathrough study completion, an average of 1 yearNumber of subjects recruited to the cohort with completed metadata and biobanked samples

Countries

Ireland

Contacts

Primary ContactAoife Cotter, PhD
aoife.cotter@ucd.ie
Backup ContactAlan Macken
alan.macken@ucd.ie

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026